Ambion Provides Additional Human Genome-Wide siRNA Libraries
News Dec 20, 2005
Ambion, Inc. has announced that the Max Planck Institute for Molecular Cell Biology and Genetics (MPI-CBG) in Dresden, Germany has received final shipment of Ambion's Genome-Wide Human siRNA Library for its research needs.
In July of this year, Marino Zerial, Director of the MPI-CBG, and colleagues published a study in the scientific journal Nature analyzing the effects of silencing human kinases on two endocytosis pathways.
"We are very happy that the MPI-CBG - one of the world's premier research institutions - chose Ambion's siRNA library as one of the primary tools for their research," commented David Dorris, Vice President of RNAi Technologies at Ambion.
"The flexibilities of formatting, quantities and replicates are very important for libraries of any type because of the downstream impact on screening time and costs."
"This flexibility for our siRNA library, coupled with industry-leading gene silencing performance, makes the Silencer® Genome-Wide Human siRNA Library the leading screening reagent for siRNA research."
In addition to supplying the MPI-CBG with a human genome-wide library, Ambion said that they had completed delivery of a Silencer Genome-wide Human siRNA Library to the MitoCheck consortium, a European Union-funded integrated, multinational research consortium.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.